Drug Trial Radar · NCT03920007
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Oct 22, 2019
Primary completion
May 19, 2023
Study completion May 19, 2027
Sponsor
- Lead sponsor
- Atsena Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA). Secondary Objective: To evaluate the efficacy of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.
Conditions
- Leber Congenital Amaurosis
- LCA
- LCA1
Interventions
ATSN-101Drug
Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
ATSN-101 Diluent SolutionDrug
Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
PrednisoneDrug
Pharmaceutical form:Tablet Route of administration: Oral
Triamcinalone AcetonideDrug
Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
1% PrednisoloneDrug
Pharmaceutical form:Suspension Route of administration: Drops
Trimethoprim/polymyxin BDrug
Pharmaceutical form:Solution Route of administration: Topical
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation PeriodTime frame: From Baseline to Week 52
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Casey Eye Institute - Oregon Health & Science University
Portland, Oregon
Scheie Eye Institute, University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.